<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2017-9-7-12</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-2428</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>ПРЕДИКТОРЫ КРАТКОСРОЧНЫХ ОСЛОЖНЕНИЙ ТРОМБОЭМБОЛИИ ЛЕГОЧНОЙ АРТЕРИИ ВЫСОКОГО И ПРОМЕЖУТОЧНОГО РИСКА</article-title><trans-title-group xml:lang="en"><trans-title>PREDICTORS OF SHORT TERM OUTCOMES IN HIGH AND MODERATE RISK PULMONARY THROMBOEMBOLISM</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кочмарева</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kochmareva </surname><given-names>Е. А.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант кафедры госпитальной терапии №1 лечебного факультета</p></bio><email xlink:type="simple">sangrija27@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кокорин</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kokorin</surname><given-names>V. А.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н, доцент кафедры госпитальной терапии №1 лечебного факультета</p></bio><email xlink:type="simple">valentinkokorin@yahoo.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Волкова</surname><given-names>А. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Volkova</surname><given-names>А. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач-кардиолог отделения анестезиологии и реанимации №9</p></bio><email xlink:type="simple">annawolk@rambler.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гордеев</surname><given-names>И. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Gordeev</surname><given-names>I. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н, профессор, зав. кафедрой госпитальной терапии №1 лечебного факультета</p></bio><email xlink:type="simple">cardio-15@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Велиев</surname><given-names>С. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Veliev </surname><given-names>S. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>директор</p></bio><email xlink:type="simple">veliev51@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гудкова</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gudkova</surname><given-names>I. А.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.х.н., с.н.с.</p></bio><email xlink:type="simple">info@biotst.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава РФ, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University (RNRMU)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ "ГКБ №15 им. О.М. Филатова ДЗМ", Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>O.M. Filatov City Clinical Hospital № 15</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ООО НПО "БиоТест", Новосибирск</institution><country>Россия</country></aff><aff xml:lang="en"><institution>LLC “BioTest”, Novosibirsk</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>14</day><month>10</month><year>2017</year></pub-date><volume>0</volume><issue>9</issue><fpage>7</fpage><lpage>12</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кочмарева Е.А., Кокорин В.А., Волкова А.Л., Гордеев И.Г., Велиев С.Н., Гудкова И.А., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Кочмарева Е.А., Кокорин В.А., Волкова А.Л., Гордеев И.Г., Велиев С.Н., Гудкова И.А.</copyright-holder><copyright-holder xml:lang="en">Kochmareva  Е.А., Kokorin V.А., Volkova А.L., Gordeev I.G., Veliev  S.N., Gudkova I.А.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/2428">https://russjcardiol.elpub.ru/jour/article/view/2428</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучить клинические, анамнестические и лабораторно-инструментальные предикторы краткосрочных осложнений тромбоэмболии легочной артерии (ТЭЛА).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование включено 136 пациентов высокого и промежуточного риска с ТЭЛА, подтвержденной по данным МСКТ. Конечными точками являлись: обструктивный шок, фатальный рецидив, летальный исход, потребность в реанимационных мероприятиях, неотложном тромболизисе или гемодинамической поддержке. Период наблюдения составлял 30 дней. Пациенты были распределены на группы осложненного (n=44) и неосложненного (n=92) течения.</p></sec><sec><title>Результаты</title><p>Результаты. Предикторами неблагоприятного течения ТЭЛА являлись: наличие хронической сердечной недостаточности II стадии (p=0,02), сахарного диабета 2 типа (p=000001), фибрилляции предсердий (p=0,001), постоянного фактора риска ВТЭ (p=0,002), синкопе (p=0,02), положительный тест на сердечный белок, связывающий жирные кислоты (сБСЖК) (p=0,00001), положительный тест на тропонин I(p=0,02), ЧСС ≥110 уд/мин (p=0,002), систолическое АД ≤100 мм рт.ст. (p=0,00001), клиренс креатинина ≤70 мл/мин (p=0,0008). Методом логистической регрессии отобрана комбинация с наиболее высокой прогностической значимостью, включающая ЧСC ≥110 уд/мин, АД ≤100 мм рт.ст., положительный тест на сБСЖК и наличие сахарного диабета. На основании коэффициентов логистической регрессии разработана шкала ROCky: ЧСC≥110 уд/мин (1,5 балла), АД ≤100 мм рт.ст. (2,5 балла), положительный тест на сБСЖК (2 балла), сахарный диабет 2 типа (2,5 балла). Определено пороговое значение для прогнозирования комбинированной конечной точки ≥2,5 (Se 84%, Sp 75%), обструктивного шока ≥3,5 (Se 83%, Sp 83%) и летального исхода в течение 30 дней ≥4,5 (Se 79%, Sp 82%). Сочетание ≥2,5 баллов по шкале ROCky и наличие ЭХОКГ-признаков дисфункции правого желудочка оказалось более эффективным, чем алгоритм Европейского общества кардиологов (2014г.) в исследуемой популяции гемодинамически стабильных пациентов в отношении обструктивного шока, фатального рецидива ТЭЛА, летального исхода и комбинированной конечной точки. </p></sec><sec><title>Выводы</title><p>Выводы. Шкала ROCky продемонстрировала высокую эффективность в отношении прогнозирования осложнений среди гемодинамически стабильных пациентов и может быть рекомендована к дальнейшему изучению и применению в клинической практике.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To investigate on the clinical, anamnestic and laboratory-instrumental predictors of short term outcomes development in pulmonary thromboembolism (PTE).</p></sec><sec><title>Material and methods</title><p>Material and methods. To the study, 136 patients included with the high and intermediate risk PTE confirmed by multispiral computed tomography. The endpoints were obstructive shock, fatal relapse, fatal outcome, necessity of resuscitation, urgent thrombolysis and hemodynamic support. Follow-up lasted for 30 days. Patients were selected to groups of complicated (n=44) and noncomplicated (n=92) course.</p></sec><sec><title>Results</title><p>Results. The predictors of adverse course of PTE were chronic heart failure of II stage (p=0,02), diabetes type 2 (p=000001), atrial fibrillation (p=0,001), permanent risk factor for PTE (p=0,002), syncope (p=0,02), positive test for the fatty acid binding cardiac protein (cFABP) (p=0,00001), troponin I positive test (p=0,02), heart rate ≥110 bpm (p=0,002), systolic BP ≤100 mmHg (p=0,00001), creatinine clearance ≤70 mL/min (p=0,0008). By the method of logistic regression a combination selected showing most predictive power, that includes heart rate ≥110 bpm, BP ≤100 mmHg, positive cFABP and diabetes. Upon the logistic regression coefficients the prediction score was formulated, named ROCky (Risk of Complications) that includes heart rate ≥110 bpm (1,5 points), BP ≤100 mmHg (2,5 pts), positive cFABP test (2 pts), diabetes type 2 (2,5 pts). The threshold estimated for prediction of combination endpoint ≥2,5 (Se 84%, Sp 75%), obstructive shock ≥3,5 (Se 83%, Sp 83%) and fatal outcome within 30 days ≥4,5 (Se 79%, Sp 82%). Combination of ≥2,5 points by ROCky and presence of echocardiographical signs of the right ventricle dysfunction showed more efficacy than the algorithm of European Society of Cardiology (2014) in the studied population of hemodynamically stable patients, for the obstructive shock, fatal relapse of PTE, fatal outcome and combination endpoint.</p></sec><sec><title>Conclusion</title><p>Conclusion. The ROCky scale has demonstrated high efficacy in prediction of complications among hemodynamically stable patients and can be recommended for further investigation and implementation into clinical practice.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>Тромбоэмболия легочной артерии</kwd><kwd>стратификация риска</kwd><kwd>предикторы неблагоприятного исхода</kwd><kwd>сердечный белок</kwd><kwd>связывающий жирные кислоты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>pulmonary embolism</kwd><kwd>risk stratification</kwd><kwd>right ventricle dysfunction</kwd><kwd>adverse outcomes predictors</kwd><kwd>cardiac protein binding fatty acids</kwd><kwd>prediction score</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008; 28(3):370–372.</mixed-citation><mixed-citation xml:lang="en">Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008; 28(3):370–372.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Konstantinides SV, Torbicki A, Agnelli G et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal 2014; 35:3033–3080 doi:10.1093/eurheartj/ehu283.</mixed-citation><mixed-citation xml:lang="en">Konstantinides SV, Torbicki A, Agnelli G et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal 2014; 35:3033–3080 doi:10.1093/eurheartj/ehu283.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lankeit M, Jimenez D, Kostrubiec M et al. Predictive value of the high-sensitivity troponin T assay and the simplified pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation 2011; 124:2716–24. doi:10.1161/CIRCULATIONAHA.111.051177.</mixed-citation><mixed-citation xml:lang="en">Lankeit M, Jimenez D, Kostrubiec M et al. Predictive value of the high-sensitivity troponin T assay and the simplified pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation 2011; 124:2716–24. doi:10.1161/CIRCULATIONAHA.111.051177.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Jiménez D, Lobo JL, Barrios D et al. Risk stratification of patients with acute symptomatic pulmonary embolism. Intern Emerg Med 2016; 11(1):11-8. doi: 10.1007/s11739-015-1388-0.</mixed-citation><mixed-citation xml:lang="en">Jiménez D, Lobo JL, Barrios D et al. Risk stratification of patients with acute symptomatic pulmonary embolism. Intern Emerg Med 2016; 11(1):11-8. doi: 10.1007/s11739-015-1388-0.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Lankeit M., Dellas C, Benz V et al. The predictive value of heart-type fatty acid-binding pro-tein is independent from symptom duration in normotensive patients with pulmonary embolism. Thromb Res 2013; 132(5):543-7.</mixed-citation><mixed-citation xml:lang="en">Lankeit M., Dellas C, Benz V et al. The predictive value of heart-type fatty acid-binding pro-tein is independent from symptom duration in normotensive patients with pulmonary embolism. Thromb Res 2013; 132(5):543-7.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bajaj A, Saleeb M, Rathor P et al. Prognostic value of troponins in acute nonmassive pulmonary embolism: A meta-analysis. Heart Lung 2015; 44(4):327-34. doi: 10.1016/j.hrtlng.2015.03.007.</mixed-citation><mixed-citation xml:lang="en">Bajaj A, Saleeb M, Rathor P et al. Prognostic value of troponins in acute nonmassive pulmonary embolism: A meta-analysis. Heart Lung 2015; 44(4):327-34. doi: 10.1016/j.hrtlng.2015.03.007.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Jiménez D, Uresandi F, Otero R et al. Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and metaanalysis. Chest 2009; 136(4):974-82. doi: 10.1378/chest.09-0608.</mixed-citation><mixed-citation xml:lang="en">Jiménez D, Uresandi F, Otero R et al. Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and metaanalysis. Chest 2009; 136(4):974-82. doi: 10.1378/chest.09-0608.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Berghaus TM, Schwaiblmair M, von Scheidt W. Renal biomarkers and prognosis in acute pul-monary embolism. Heart 2012; 98(16):1185-6. doi: 10.1136/heartjnl-2012-302298.</mixed-citation><mixed-citation xml:lang="en">Berghaus TM, Schwaiblmair M, von Scheidt W. Renal biomarkers and prognosis in acute pul-monary embolism. Heart 2012; 98(16):1185-6. doi: 10.1136/heartjnl-2012-302298.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Huang W, Goldberg RJ, Anderson FA et al. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009) Am J Med 2014; 127(829–839):e825.</mixed-citation><mixed-citation xml:lang="en">Huang W, Goldberg RJ, Anderson FA et al. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009) Am J Med 2014; 127(829–839):e825.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bajaj A, Rathor P, Sehgal V et al. Prognostic Value of Biomarkers in Acute Non-massive Pul-monary Embolism: A Systematic Review and Meta-analysis. Lung 2015; 193(5):639-51. doi: 10.1007/s00408-015-9752-4.</mixed-citation><mixed-citation xml:lang="en">Bajaj A, Rathor P, Sehgal V et al. Prognostic Value of Biomarkers in Acute Non-massive Pul-monary Embolism: A Systematic Review and Meta-analysis. Lung 2015; 193(5):639-51. doi: 10.1007/s00408-015-9752-4.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Bajaj A, Rathor P, Sehgal V et al. Risk stratification in acute pulmonary embolism with heart-type fatty acid-binding protein: A meta-analysis. J Crit Care 2015; 30(5):1151.e1-7. doi: 10.1016/j.jcrc.2015.05.026.</mixed-citation><mixed-citation xml:lang="en">Bajaj A, Rathor P, Sehgal V et al. Risk stratification in acute pulmonary embolism with heart-type fatty acid-binding protein: A meta-analysis. J Crit Care 2015; 30(5):1151.e1-7. doi: 10.1016/j.jcrc.2015.05.026.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
